Open AccessStandard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease
Author(s) -
Surein Arulananda,
Hongdo Do,
Gareth Rivalland,
Zoë Loh,
Ashan Musafer,
Eddie Lau,
Paul Mitchell,
Alexander Dobrovic,
Thomas John
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.05.41
Subject(s) - osimertinib , t790m , medicine , erlotinib , lung cancer , epidermal growth factor receptor , oncology , resistance mutation , pathology , cancer research , cancer , gefitinib , biology , reverse transcriptase , rna , biochemistry , gene
Leptomeningeal spread in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations who experience disease progression on TKIs portends a poor prognosis. Mutation profiling of tumour DNA in cerebrospinal fluid (CSF) samples can be used to determine the presence of the EGFR T790M resistance mutation, indicating that osimertinib, a CNS-penetrating 3 rd generation TKI may be efficacious.